AbbVie exec sells 32,710 shares after option exercise
AbbVie Inc. (ABBV) reported insider equity transactions by EVP and Chief Business/Strategy Officer Nicholas Donoghoe on August 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AbbVie Inc. (ABBV) reported insider equity transactions by EVP and Chief Business/Strategy Officer Nicholas Donoghoe on August 14, 2026. Donoghoe exercised employee stock options for 32,710 shares of common stock at an exercise price of $79.02 per share under AbbVie’s 2013 incentive stock program, then sold 32,710 shares of common stock in a separate transaction. The options exercised were from a grant that vested in annual increments between 2020 and 2022 and now show 0 options remaining from this specific grant.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Donoghoe Nicholas
Role
EVP, CHIEF BUS/STRAT OFFICER
Sold
32,710 shs ($8.18M)
Approx. gross sale proceeds
$8.18M
Approx. exercise cost
$2.58M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (Right to buy) F1 | 32,710 | $0.00 | $0.00 |
| Exercise | Common Stock, $0.01 par value | 32,710 | $79.02 | $2.58M |
| Sale | Common Stock, $0.01 par value | 32,710 | $250.00 | $8.18M |
Holdings After Transaction:
Option (Right to buy) — 0 contracts (Direct);
Common Stock, $0.01 par value — 74,430 shares (Direct)
Footnotes (1)
- F1. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.
Key Figures
Options exercised: 32,710 shares
Option exercise price: $79.02 per share
Shares sold: 32,710 shares
+3 more
6 metrics
Options exercised
32,710 shares
Employee stock options exercised on August 14, 2026
Option exercise price
$79.02 per share
Exercise or conversion price of options into AbbVie common stock
Shares sold
32,710 shares
AbbVie common stock sold in non-derivative transaction on August 14, 2026
Sale price
$250.00 per share
Per-share price reported for the common stock sale
Option expiration date
2029-02-20
Original expiration date of the employee stock option grant
Options after transaction
0 shares
Total options remaining from this specific grant after exercise
Key Terms
Employee stock option, Amended and Restated 2013 Incentive Stock Program, Section 16, Rule 16b-3
4 terms
Employee stock option financial
"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Amended and Restated 2013 Incentive Stock Program financial
"granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program"
Section 16 regulatory
"in a transaction exempt from Section 16 under Rule 16b-3"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Rule 16b-3 regulatory
"in a transaction exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ABBV executive Nicholas Donoghoe report on August 14, 2026?
Nicholas Donoghoe reported exercising 32,710 stock options at $79.02 per share and selling 32,710 AbbVie common shares on August 14, 2026. The option grant involved became fully exercisable between 2020 and 2022.
How many AbbVie (ABBV) stock options did Nicholas Donoghoe exercise and at what price?
He exercised 32,710 options to buy AbbVie common stock at an exercise price of $79.02 per share. These options came from a grant under AbbVie’s Amended and Restated 2013 Incentive Stock Program.
What does the Form 4 say about remaining options from Nicholas Donoghoe’s AbbVie grant?
The filing shows 0 options remaining from this specific AbbVie option grant after exercising 32,710 options. The grant vested in annual increments in 2020, 2021, and 2022 under the company’s 2013 incentive program.
Were Nicholas Donoghoe’s AbbVie (ABBV) transactions under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan for these transactions. The footnote instead describes the grant as an employee stock option under AbbVie’s 2013 incentive stock program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
